Numbers & figures
Curious about the size of the impact of the Horizon Europe programme? Check out the numbers & figures.
Statistics from Flanders
Several editions of the Speurgids Ondernemen en Innoveren (Dutch) from EWI (Department of Economy, Science and Innovation) offer statistics on Flemish participation in the European programmes. The latest edition (2023) can be found here and includes separate chapters on Horizon 2020 & Horizon Europe (Deel 5: Analyse van de Kaderprogramma’s Horizon 2020 en Horizon Europe) and on Digital Europe (Deel 6: Het Digital Europe Programma Vlaanderen).
The bi-annual Vlaams Indicatorenboek (Dutch) by the Interuniversity Centre for Research and Development Monitoring (ECOOM) provides numbers on Flemish participation in Horizon 2020 and Horizon Europe. The latest edition (2023) is available here & chapter 5 on the EU Framework Programmes of Research & Innovation can be consulted here.
Statistics from Europe
Horizon Dashboard provides data on proposals, projects and participants. There are several tutorials available on the EU Science and Innovation You Tube channel which explain how to make the best use of it
Horizon 2020 country profiles provide country level numbers on participation in Horizon 2020 . Currently, there are no country profiles available yet for Horizon Europe.
DIGITAL Dashboard displays data about Digital Europe grants, providing an interface with numerous filters allowing to personalise the information searched.
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
